Deregulation of the PI3K/AKT/mTOR pathway is the most
frequently observed signaling alteration in cancer
1
Molecular alterations at multiple levels of the
PI3K/AKT/mTOR pathway have been reported including:
1–3
Activating mutations and/or overexpression of RTKs
2
Activating mutations and/or amplifications of PI3Ks
1
Inactivating mutations or deletion of PTEN
1,3
Deregulation of the PI3K/AKT/mTOR Pathway in Cancer
mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol 3-kinase; PTEN, phosphatase and tensin homolog;
RTK, receptor tyrosine kinase.
1. Liu P,
et al. Nat Rev Drug Discov
2009;8:627–644; 2. Turner N,
et al. Cancer Res
2010;1;70:2085–2094; 3. Li J,
et al. Science
1997;275:1943–1947.
